RA Capital Nexus Fund II, L.P.
Insider CIK 1825376 · ABOS Director, 10% owner · DICE Director, 10% owner · SPRY Director · ELYM Director, 10% owner · ACRV Director, 10% owner · BOLD 10% owner · HOWL Director, 10% owner · ICVX Director, 10% owner · LENZ Director, 10% owner · JANX Director · CTKB Director · PEPG Director, 10% owner · ANTX 10% owner · FRNM Director · COAG Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CLYM Climb Bio, Inc. | M Exercise deriv | 2026-09-28 | 2026-09-30 | 10,000 | — | $0 | 0 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise deriv | 2026-09-28 | 2026-09-30 | 40,000 | — | $0 | 0 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise deriv | 2026-09-28 | 2026-09-30 | 10,000 | — | $0 | 0 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise deriv | 2026-09-28 | 2026-09-30 | 10,000 | — | $0 | 0 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise | 2026-09-28 | 2026-09-30 | 10,000 | $3.00 | $30.0K | 20,000 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise | 2026-09-28 | 2026-09-30 | 10,000 | $3.46 | $34.6K | 10,000 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise | 2026-09-28 | 2026-09-30 | 40,000 | $1.29 | $51.6K | 70,000 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise | 2026-09-28 | 2026-09-30 | 10,000 | $7.89 | $78.9K | 30,000 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise deriv | 2026-09-28 | 2026-09-30 | 40,000 | — | $0 | 0 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise deriv | 2026-09-28 | 2026-09-30 | 10,000 | — | $0 | 0 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise deriv | 2026-09-28 | 2026-09-30 | 10,000 | — | $0 | 0 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise deriv | 2026-09-28 | 2026-09-30 | 10,000 | — | $0 | 0 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise | 2026-09-28 | 2026-09-30 | 40,000 | $1.29 | $51.6K | 70,000 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise | 2026-09-28 | 2026-09-30 | 10,000 | $7.89 | $78.9K | 30,000 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise | 2026-09-28 | 2026-09-30 | 10,000 | $3.00 | $30.0K | 20,000 | SEC↗ |
| CLYM Climb Bio, Inc. | M Exercise | 2026-09-28 | 2026-09-30 | 10,000 | $3.46 | $34.6K | 10,000 | SEC↗ |
| FRNM Freenome, Inc. | A Award | 2026-07-20 | 2026-07-22 | 336,965 | $10.00 | $3.37M | 1,245,068 | SEC↗ |
| FRNM Freenome, Inc. | A Award | 2026-07-20 | 2026-07-22 | 4,918,411 | $10.00 | $49.18M | 12,230,122 | SEC↗ |
| FRNM Freenome, Inc. | A Award | 2026-07-20 | 2026-07-22 | 367,427 | — | $0 | 367,427 | SEC↗ |
| FRNM Freenome, Inc. | A Award | 2026-07-20 | 2026-07-22 | 908,103 | — | $0 | 908,103 | SEC↗ |
| FRNM Freenome, Inc. | A Award | 2026-07-20 | 2026-07-22 | 553,703 | — | $0 | 553,703 | SEC↗ |
| FRNM Freenome, Inc. | A Award | 2026-07-20 | 2026-07-22 | 970,950 | — | $0 | 970,950 | SEC↗ |
| FRNM Freenome, Inc. | A Award | 2026-07-20 | 2026-07-22 | 6,561,711 | — | $0 | 7,311,711 | SEC↗ |
| CLYM Climb Bio, Inc. | A Award deriv | 2026-06-29 | 2026-07-01 | 70,284 | — | $0 | 70,284 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2026-06-24 | 2026-06-26 | 30,000 | — | $0 | 30,000 | SEC↗ |
| PEPG PepGen Inc. | A Award deriv | 2026-06-18 | 2026-06-22 | 34,000 | — | $0 | 34,000 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2026-06-17 | 2026-06-22 | 20,275 | — | $0 | 20,275 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | A Award deriv | 2026-06-15 | 2026-06-15 | 22,100 | — | $0 | 22,100 | SEC↗ |
| JANX Janux Therapeutics, Inc. | A Award deriv | 2026-06-11 | 2026-06-12 | 15,500 | — | $0 | 15,500 | SEC↗ |
| JANX Janux Therapeutics, Inc. | A Award | 2026-06-11 | 2026-06-12 | 5,500 | — | $0 | 11,750 | SEC↗ |
| CLYM Climb Bio, Inc. | A Award deriv | 2026-06-05 | 2026-06-08 | 40,000 | — | $0 | 40,000 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | A Award deriv | 2026-06-03 | 2026-06-05 | 53,250 | — | $0 | 53,250 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | A Award | 2026-06-03 | 2026-06-05 | 35,500 | — | $0 | 48,300 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award | 2026-05-18 | 2026-05-20 | 9,366 | — | $0 | 9,366 | SEC↗ |
| COAG Hemab Therapeutics Holding | P Buy | 2026-05-06 | 2026-05-06 | 14,611 | $23.77 | $347.3K | 6,261,118 | SEC↗ |
| COAG Hemab Therapeutics Holding | P Buy | 2026-05-06 | 2026-05-06 | 53,407 | $24.83 | $1.33M | 6,314,525 | SEC↗ |
| COAG Hemab Therapeutics Holding | P Buy | 2026-05-05 | 2026-05-06 | 87,143 | $24.59 | $2.14M | 6,236,239 | SEC↗ |
| COAG Hemab Therapeutics Holding | P Buy | 2026-05-05 | 2026-05-06 | 10,268 | $25.00 | $256.7K | 6,246,507 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion deriv | 2026-05-04 | 2026-05-06 | 56,972 | — | $0 | 0 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion deriv | 2026-05-04 | 2026-05-06 | 64,680 | — | $0 | 0 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion deriv | 2026-05-04 | 2026-05-06 | 27,720 | — | $0 | 0 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion deriv | 2026-05-04 | 2026-05-06 | 10,054 | — | $0 | 0 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion deriv | 2026-05-04 | 2026-05-06 | 18,146 | — | $0 | 0 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion deriv | 2026-05-04 | 2026-05-06 | 42,341 | — | $0 | 0 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion | 2026-05-04 | 2026-05-06 | 1,009,052 | — | $0 | 1,009,052 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion | 2026-05-04 | 2026-05-06 | 221,188 | — | $0 | 221,188 | SEC↗ |
| COAG Hemab Therapeutics Holding | P Buy | 2026-05-04 | 2026-05-06 | 2,541,250 | $18.00 | $45.74M | 6,149,096 | SEC↗ |
| COAG Hemab Therapeutics Holding | P Buy | 2026-05-04 | 2026-05-06 | 133,750 | $18.00 | $2.41M | 354,938 | SEC↗ |
| COAG Hemab Therapeutics Holding | C Conversion | 2026-05-04 | 2026-05-06 | 3,607,846 | — | $0 | 3,607,846 | SEC↗ |
| CLYM Climb Bio, Inc. | A Award deriv | 2026-04-29 | 2026-04-29 | 2,106,000 | $9.50 | $20.01M | 22,546,000 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award | 2026-04-22 | 2026-04-23 | 3,888,888 | $1.80 | $7.00M | 11,803,094 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | A Award | 2026-03-16 | 2026-03-18 | 6,060,606 | $3.30 | $20.00M | 19,103,785 | SEC↗ |
| CLYM Climb Bio, Inc. | P Buy | 2026-01-05 | 2026-01-07 | 7,111 | $3.50 | $24.9K | 3,403,429 | SEC↗ |
| CLYM Climb Bio, Inc. | P Buy | 2025-12-12 | 2025-12-15 | 101,462 | $2.86 | $290.2K | 3,396,318 | SEC↗ |
| CLYM Climb Bio, Inc. | A Award deriv | 2025-12-11 | 2025-12-15 | 20,440,000 | — | $0 | 20,440,000 | SEC↗ |
| CLYM Climb Bio, Inc. | D To issuer | 2025-12-11 | 2025-12-15 | 20,440,000 | — | $0 | 3,081,757 | SEC↗ |
| CLYM Climb Bio, Inc. | P Buy | 2025-12-11 | 2025-12-15 | 213,099 | $2.18 | $464.6K | 3,294,856 | SEC↗ |
| PEPG PepGen Inc. | P Buy | 2025-09-26 | 2025-09-30 | 9,375,000 | $3.20 | $30.00M | 18,554,273 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2025-06-25 | 2025-06-27 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2025-06-13 | 2025-06-17 | 20,275 | — | $0 | 20,275 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | A Award deriv | 2025-06-11 | 2025-06-11 | 13,500 | — | $0 | 13,500 | SEC↗ |
| JANX Janux Therapeutics, Inc. | A Award deriv | 2025-06-11 | 2025-06-13 | 11,667 | — | $0 | 11,667 | SEC↗ |
| JANX Janux Therapeutics, Inc. | A Award | 2025-06-11 | 2025-06-13 | 3,750 | — | $0 | 6,250 | SEC↗ |
| CLYM Climb Bio, Inc. | A Award deriv | 2025-06-04 | 2025-06-05 | 40,000 | — | $0 | 40,000 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | A Award deriv | 2025-06-04 | 2025-06-05 | 19,500 | — | $0 | 19,500 | SEC↗ |
| PEPG PepGen Inc. | A Award deriv | 2025-06-04 | 2025-06-06 | 16,000 | — | $0 | 16,000 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | A Award | 2025-06-04 | 2025-06-05 | 12,800 | — | $0 | 12,800 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | P Buy | 2025-05-14 | 2025-05-14 | 162,539 | $0.98 | $159.3K | 6,237,482 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | P Buy | 2025-05-13 | 2025-05-14 | 52,974 | $0.98 | $51.9K | 6,074,943 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | P Buy | 2025-05-12 | 2025-05-14 | 320,913 | $0.86 | $276.0K | 6,021,969 | SEC↗ |
| JANX Janux Therapeutics, Inc. | P Buy | 2025-03-07 | 2025-03-07 | 110,206 | $31.02 | $3.42M | 10,141,287 | SEC↗ |
| JANX Janux Therapeutics, Inc. | P Buy | 2025-03-06 | 2025-03-07 | 372,093 | $30.78 | $11.45M | 10,031,081 | SEC↗ |
| JANX Janux Therapeutics, Inc. | P Buy | 2025-03-05 | 2025-03-07 | 37,455 | $31.30 | $1.17M | 9,658,988 | SEC↗ |
| JANX Janux Therapeutics, Inc. | P Buy | 2025-03-05 | 2025-03-07 | 304,287 | $30.56 | $9.30M | 9,621,533 | SEC↗ |
| JANX Janux Therapeutics, Inc. | P Buy | 2024-10-18 | 2024-10-22 | 1,200,000 | $44.75 | $53.70M | 9,317,246 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2024-08-09 | 2024-08-13 | 3,410,335 | $1.08 | $3.68M | 1,725,348 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2024-08-09 | 2024-08-13 | 114,759 | $1.08 | $123.9K | 300,853 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | P Buy | 2024-06-27 | 2024-07-01 | 1,059,375 | $3.84 | $4.07M | 2,866,375 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | P Buy | 2024-06-27 | 2024-07-01 | 11,949,171 | $3.84 | $45.88M | 23,521,757 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | A Award | 2024-06-27 | 2024-07-01 | 973,000 | — | $0 | 11,572,586 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | A Award | 2024-06-27 | 2024-07-01 | 1,807,000 | — | $0 | 1,807,000 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | A Award | 2024-06-27 | 2024-07-01 | 2,479,872 | — | $0 | 2,479,872 | SEC↗ |
| JANX Janux Therapeutics, Inc. | A Award deriv | 2024-06-26 | 2024-06-28 | 8,350 | — | $0 | 8,350 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | A Award deriv | 2024-06-26 | 2024-06-28 | 10,000 | — | $0 | 10,000 | SEC↗ |
| JANX Janux Therapeutics, Inc. | A Award | 2024-06-26 | 2024-06-28 | 2,500 | — | $0 | 2,500 | SEC↗ |
| PEPG PepGen Inc. | A Award deriv | 2024-06-20 | 2024-06-21 | 13,000 | — | $0 | 13,000 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2024-06-20 | 2024-06-24 | 40,000 | — | $0 | 40,000 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2024-06-20 | 2024-06-24 | 20,275 | — | $0 | 20,275 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | A Award deriv | 2024-06-10 | 2024-06-10 | 25,000 | — | $0 | 25,000 | SEC↗ |
| HOWL Werewolf Therapeutics, Inc | A Award deriv | 2024-05-24 | 2024-05-24 | 17,500 | — | $0 | 17,500 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award | 2024-04-11 | 2024-04-15 | 3,530,000 | $8.50 | $30.00M | 7,914,206 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 3,000,000 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 17,000,000 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 13,964,285 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion deriv | 2024-04-02 | 2024-04-04 | 2,464,286 | — | $0 | 0 | SEC↗ |
| BOLD Boundless Bio, Inc. | P Buy | 2024-04-02 | 2024-04-04 | 296,875 | $16.00 | $4.75M | 1,884,787 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion | 2024-04-02 | 2024-04-04 | 280,219 | — | $0 | 280,219 | SEC↗ |
| BOLD Boundless Bio, Inc. | P Buy | 2024-04-02 | 2024-04-04 | 15,625 | $16.00 | $250.0K | 295,844 | SEC↗ |
| BOLD Boundless Bio, Inc. | C Conversion | 2024-04-02 | 2024-04-04 | 1,587,912 | — | $0 | 1,587,912 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | P Buy | 2024-03-27 | 2024-03-27 | 505,954 | $9.79 | $4.95M | 9,958,073 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | P Buy | 2024-03-26 | 2024-03-27 | 457,745 | $9.55 | $4.37M | 9,452,119 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | P Buy | 2024-03-25 | 2024-03-27 | 437,600 | $9.06 | $3.96M | 8,994,374 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | A Award deriv | 2024-03-21 | 2024-03-25 | 10,580 | — | $0 | 10,580 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | A Award deriv | 2024-03-21 | 2024-03-25 | 5,371 | — | $0 | 5,371 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | A Award deriv | 2024-03-21 | 2024-03-25 | 27,000 | — | $0 | 27,000 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | A Award deriv | 2024-03-21 | 2024-03-25 | 54,582 | — | $0 | 54,582 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | A Award | 2024-03-21 | 2024-03-25 | 164,729 | — | $0 | 164,729 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | A Award | 2024-03-21 | 2024-03-25 | 694,755 | — | $0 | 694,755 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | A Award | 2024-03-21 | 2024-03-25 | 2,386,301 | — | $0 | 2,386,301 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | P Buy | 2024-03-21 | 2024-03-25 | 933,038 | $15.03 | $14.02M | 3,319,339 | SEC↗ |
| LENZ LENZ Therapeutics, Inc. | P Buy | 2024-03-21 | 2024-03-25 | 64,971 | $15.03 | $976.5K | 694,755 | SEC↗ |
| JANX Janux Therapeutics, Inc. | P Buy deriv | 2024-03-04 | 2024-03-06 | 1,397,849 | $46.50 | $65.00M | 1,397,849 | SEC↗ |
| ICVX Icosavax, Inc. | D To issuer deriv | 2024-02-19 | 2024-02-20 | 22,278 | — | $0 | 0 | SEC↗ |
| ICVX Icosavax, Inc. | D To issuer deriv | 2024-02-19 | 2024-02-20 | 17,000 | — | $0 | 0 | SEC↗ |
| ICVX Icosavax, Inc. | U Tender | 2024-02-19 | 2024-02-20 | 5,543 | — | $0 | 0 | SEC↗ |
| ICVX Icosavax, Inc. | U Tender | 2024-02-19 | 2024-02-20 | 5,324,897 | — | $0 | 0 | SEC↗ |
| ICVX Icosavax, Inc. | U Tender | 2024-02-19 | 2024-02-20 | 638,668 | — | $0 | 0 | SEC↗ |
| PEPG PepGen Inc. | P Buy | 2024-02-09 | 2024-02-13 | 2,557,593 | $10.64 | $27.21M | 9,179,273 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | P Buy | 2023-09-21 | 2023-09-25 | 2,508,691 | $2.97 | $7.45M | 8,365,465 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | P Buy | 2023-09-21 | 2023-09-25 | 191,309 | $3.83 | $732.7K | 8,556,774 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | P Buy | 2023-08-29 | 2023-08-31 | 3,750,000 | $6.20 | $23.25M | 5,856,774 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2023-08-18 | 2023-08-22 | 1,777,778 | $9.00 | $16.00M | 5,135,683 | SEC↗ |
| DICE DICE Therapeutics, Inc. | D To issuer deriv | 2023-08-09 | 2023-08-09 | 21,250 | — | $0 | 0 | SEC↗ |
| DICE DICE Therapeutics, Inc. | U Tender | 2023-08-09 | 2023-08-09 | 786,407 | — | $0 | 0 | SEC↗ |
| DICE DICE Therapeutics, Inc. | U Tender | 2023-08-09 | 2023-08-09 | 7,070,205 | — | $0 | 0 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | P Buy | 2023-07-21 | 2023-07-25 | 5,161,290 | $7.75 | $40.00M | 13,043,179 | SEC↗ |
| JANX Janux Therapeutics, Inc. | P Buy deriv | 2023-07-19 | 2023-07-21 | 503,226 | $12.46 | $6.27M | 503,226 | SEC↗ |
| JANX Janux Therapeutics, Inc. | P Buy | 2023-07-19 | 2023-07-21 | 495,008 | $12.46 | $6.17M | 8,117,246 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award deriv | 2023-06-27 | 2023-06-28 | 40,000 | — | $0 | 40,000 | SEC↗ |
| JANX Janux Therapeutics, Inc. | A Award deriv | 2023-06-14 | 2023-06-16 | 12,500 | — | $0 | 12,500 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | A Award deriv | 2023-06-06 | 2023-06-13 | 25,000 | — | $0 | 25,000 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | A Award deriv | 2023-05-18 | 2023-05-22 | 10,000 | — | $0 | 10,000 | SEC↗ |
| DICE DICE Therapeutics, Inc. | P Buy | 2023-03-30 | 2023-03-30 | 195,997 | $28.74 | $5.63M | 7,070,205 | SEC↗ |
| DICE DICE Therapeutics, Inc. | P Buy | 2023-03-29 | 2023-03-30 | 66,369 | $29.38 | $1.95M | 6,874,208 | SEC↗ |
| DICE DICE Therapeutics, Inc. | P Buy | 2023-03-28 | 2023-03-30 | 246,779 | $29.24 | $7.22M | 6,807,839 | SEC↗ |
| DICE DICE Therapeutics, Inc. | P Buy | 2023-03-27 | 2023-03-27 | 151,132 | $27.48 | $4.15M | 6,561,060 | SEC↗ |
| DICE DICE Therapeutics, Inc. | P Buy | 2023-03-24 | 2023-03-27 | 192,335 | $26.87 | $5.17M | 6,409,928 | SEC↗ |
| DICE DICE Therapeutics, Inc. | P Buy | 2023-03-23 | 2023-03-27 | 155,089 | $26.67 | $4.14M | 6,217,593 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | C Conversion deriv | 2022-11-17 | 2022-11-21 | 1,051,263 | — | $0 | 0 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | C Conversion deriv | 2022-11-17 | 2022-11-21 | 2,452,947 | — | $0 | 0 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | C Conversion | 2022-11-17 | 2022-11-21 | 994,706 | — | $0 | 994,706 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | P Buy | 2022-11-17 | 2022-11-21 | 3,389,500 | $12.50 | $42.37M | 4,384,206 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | C Conversion | 2022-11-17 | 2022-11-21 | 426,302 | — | $0 | 426,302 | SEC↗ |
| ACRV Acrivon Therapeutics, Inc. | A Award deriv | 2022-11-14 | 2022-11-16 | 35,235 | — | $0 | 35,235 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award | 2022-11-08 | 2022-11-10 | 902,904 | — | $0 | 902,904 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | A Award | 2022-11-08 | 2022-11-10 | 2,106,774 | — | $0 | 2,106,774 | SEC↗ |
| DICE DICE Therapeutics, Inc. | P Buy | 2022-10-17 | 2022-10-19 | 1,640,000 | $36.50 | $59.86M | 6,848,911 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-08-04 | 2022-08-05 | 100 | $7.99 | $799 | 3,773,517 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-08-03 | 2022-08-05 | 1,809 | $7.48 | $13.5K | 3,773,417 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-07-27 | 2022-07-28 | 8,281 | $7.91 | $65.5K | 3,771,608 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-07-26 | 2022-07-28 | 14,938 | $7.71 | $115.2K | 3,763,327 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-06-21 | 2022-06-23 | 302 | $7.99 | $2.4K | 3,748,389 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | A Award deriv | 2022-06-15 | 2022-06-21 | 25,000 | — | $0 | 25,000 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-06-14 | 2022-06-15 | 61,424 | $7.97 | $489.5K | 3,748,087 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-06-13 | 2022-06-15 | 20,000 | $7.90 | $158.0K | 3,686,663 | SEC↗ |
| ICVX Icosavax, Inc. | A Award deriv | 2022-06-10 | 2022-06-14 | 22,278 | — | $0 | 22,278 | SEC↗ |
| ICVX Icosavax, Inc. | A Award | 2022-06-10 | 2022-06-14 | 5,543 | — | $0 | 5,543 | SEC↗ |
| DICE DICE Therapeutics, Inc. | A Award deriv | 2022-06-07 | 2022-06-08 | 21,250 | — | $0 | 21,250 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | A Award deriv | 2022-05-19 | 2022-06-01 | 10,000 | — | $0 | 10,000 | SEC↗ |
| PEPG PepGen Inc. | C Conversion deriv | 2022-05-10 | 2022-05-12 | 646,306 | — | $0 | 0 | SEC↗ |
| PEPG PepGen Inc. | C Conversion deriv | 2022-05-10 | 2022-05-12 | 2,199,741 | — | $0 | 0 | SEC↗ |
| PEPG PepGen Inc. | C Conversion deriv | 2022-05-10 | 2022-05-12 | 425,497 | — | $0 | 0 | SEC↗ |
| PEPG PepGen Inc. | C Conversion deriv | 2022-05-10 | 2022-05-12 | 211,410 | — | $0 | 0 | SEC↗ |
| PEPG PepGen Inc. | C Conversion deriv | 2022-05-10 | 2022-05-12 | 1,508,048 | — | $0 | 0 | SEC↗ |
| PEPG PepGen Inc. | C Conversion | 2022-05-10 | 2022-05-12 | 3,642,229 | — | $0 | 3,642,229 | SEC↗ |
| PEPG PepGen Inc. | P Buy | 2022-05-10 | 2022-05-12 | 249,749 | $12.00 | $3.00M | 1,302,600 | SEC↗ |
| PEPG PepGen Inc. | C Conversion | 2022-05-10 | 2022-05-12 | 207,672 | — | $0 | 207,672 | SEC↗ |
| PEPG PepGen Inc. | C Conversion | 2022-05-10 | 2022-05-12 | 1,052,851 | — | $0 | 1,052,851 | SEC↗ |
| PEPG PepGen Inc. | P Buy | 2022-05-10 | 2022-05-12 | 2,979,451 | $12.00 | $35.75M | 6,621,680 | SEC↗ |
| PEPG PepGen Inc. | A Award deriv | 2022-05-06 | 2022-05-10 | 11,667 | — | $0 | 11,667 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion deriv | 2022-03-29 | 2022-03-31 | 1,699,998 | — | $0 | 0 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion deriv | 2022-03-29 | 2022-03-31 | 299,999 | — | $0 | 0 | SEC↗ |
| ICVX Icosavax, Inc. | P Buy | 2022-03-29 | 2022-03-30 | 8,900 | $4.75 | $42.3K | 5,963,565 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-03-29 | 2022-03-31 | 1,551,053 | $15.00 | $23.27M | 3,251,051 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion | 2022-03-29 | 2022-03-31 | 1,699,998 | — | $0 | 1,699,998 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion | 2022-03-29 | 2022-03-31 | 299,999 | — | $0 | 299,999 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-03-29 | 2022-03-31 | 115,613 | $15.00 | $1.73M | 415,612 | SEC↗ |
| ICVX Icosavax, Inc. | P Buy | 2022-03-28 | 2022-03-30 | 175,318 | $4.53 | $794.2K | 5,953,665 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-03-15 | 2022-03-16 | 241,727 | $12.27 | $2.97M | 13,381,054 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-03-14 | 2022-03-16 | 342,143 | $12.35 | $4.23M | 13,139,327 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-03-11 | 2022-03-11 | 337,492 | $12.77 | $4.31M | 12,797,184 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-03-10 | 2022-03-11 | 256,992 | $12.95 | $3.33M | 12,459,692 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-03-09 | 2022-03-11 | 40,154 | $12.99 | $521.6K | 12,202,700 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-03-08 | 2022-03-08 | 245,701 | $12.86 | $3.16M | 12,162,546 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-03-07 | 2022-03-08 | 337,901 | $12.61 | $4.26M | 11,916,845 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-03-04 | 2022-03-08 | 63,662 | $12.99 | $827.0K | 11,578,944 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-03-02 | 2022-03-02 | 138,255 | $12.89 | $1.78M | 11,515,282 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-03-01 | 2022-03-02 | 294,864 | $12.98 | $3.83M | 11,377,027 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-02-28 | 2022-03-02 | 8,746 | $12.97 | $113.4K | 11,082,163 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-02-25 | 2022-02-25 | 18,991 | $12.99 | $246.7K | 11,073,417 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-02-24 | 2022-02-25 | 186,467 | $13.03 | $2.43M | 11,054,426 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-02-23 | 2022-02-25 | 214,922 | $13.41 | $2.88M | 10,867,959 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-02-22 | 2022-02-22 | 214,922 | $13.46 | $2.89M | 10,653,037 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-02-18 | 2022-02-22 | 166,229 | $14.12 | $2.35M | 10,438,115 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-02-17 | 2022-02-22 | 166,229 | $14.78 | $2.46M | 10,271,886 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-02-16 | 2022-02-16 | 166,200 | $14.98 | $2.49M | 10,105,657 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-02-15 | 2022-02-16 | 166,200 | $14.99 | $2.49M | 9,939,457 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2022-02-14 | 2022-02-16 | 166,229 | $14.72 | $2.45M | 9,773,257 | SEC↗ |
| DICE DICE Therapeutics, Inc. | C Conversion deriv | 2021-09-17 | 2021-09-20 | 274,986 | — | $0 | 0 | SEC↗ |
| DICE DICE Therapeutics, Inc. | C Conversion deriv | 2021-09-17 | 2021-09-20 | 433,843 | — | $0 | 0 | SEC↗ |
| DICE DICE Therapeutics, Inc. | C Conversion deriv | 2021-09-17 | 2021-09-20 | 641,635 | — | $0 | 0 | SEC↗ |
| DICE DICE Therapeutics, Inc. | C Conversion deriv | 2021-09-17 | 2021-09-20 | 2,458,447 | — | $0 | 0 | SEC↗ |
| DICE DICE Therapeutics, Inc. | P Buy | 2021-09-17 | 2021-09-20 | 77,578 | $17.00 | $1.32M | 786,407 | SEC↗ |
| DICE DICE Therapeutics, Inc. | C Conversion | 2021-09-17 | 2021-09-20 | 3,100,082 | — | $0 | 3,100,082 | SEC↗ |
| DICE DICE Therapeutics, Inc. | P Buy | 2021-09-17 | 2021-09-20 | 1,322,422 | $17.00 | $22.48M | 4,422,504 | SEC↗ |
| DICE DICE Therapeutics, Inc. | C Conversion | 2021-09-17 | 2021-09-20 | 708,829 | — | $0 | 708,829 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion deriv | 2021-08-12 | 2021-08-16 | 708,333 | — | $0 | 0 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion deriv | 2021-08-12 | 2021-08-16 | 673,076 | — | $0 | 0 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion deriv | 2021-08-12 | 2021-08-16 | 1,415,002 | — | $0 | 0 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion deriv | 2021-08-12 | 2021-08-16 | 2,639,507 | — | $0 | 0 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion deriv | 2021-08-12 | 2021-08-16 | 139,481 | — | $0 | 0 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion deriv | 2021-08-12 | 2021-08-16 | 485,493 | — | $0 | 0 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion deriv | 2021-08-12 | 2021-08-16 | 288,461 | — | $0 | 0 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion deriv | 2021-08-12 | 2021-08-16 | 518,164 | — | $0 | 0 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion | 2021-08-12 | 2021-08-16 | 288,461 | — | $0 | 288,461 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion | 2021-08-12 | 2021-08-16 | 4,727,585 | — | $0 | 7,594,804 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion | 2021-08-12 | 2021-08-16 | 624,974 | — | $0 | 841,087 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | P Buy | 2021-08-12 | 2021-08-16 | 195,218 | $12.50 | $2.44M | 483,679 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | C Conversion | 2021-08-12 | 2021-08-16 | 1,226,497 | — | $0 | 1,226,497 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | P Buy | 2021-08-12 | 2021-08-16 | 3,004,782 | $12.50 | $37.56M | 10,599,586 | SEC↗ |
| ELYM Eliem Therapeutics, Inc. | A Award deriv | 2021-08-09 | 2021-08-11 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ICVX Icosavax, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 10,995,066 | — | $0 | 0 | SEC↗ |
| ICVX Icosavax, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 1,940,306 | — | $0 | 0 | SEC↗ |
| ICVX Icosavax, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 2,645,779 | — | $0 | 2,645,779 | SEC↗ |
| ICVX Icosavax, Inc. | P Buy | 2021-08-02 | 2021-08-04 | 2,494,900 | $15.00 | $37.42M | 5,140,679 | SEC↗ |
| ICVX Icosavax, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 466,902 | — | $0 | 466,902 | SEC↗ |
| ICVX Icosavax, Inc. | P Buy | 2021-08-02 | 2021-08-04 | 171,766 | $15.00 | $2.58M | 638,668 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | C Conversion deriv | 2021-07-27 | 2021-07-29 | 998,553 | — | $0 | 0 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | C Conversion deriv | 2021-07-27 | 2021-07-29 | 507,724 | — | $0 | 0 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | C Conversion deriv | 2021-07-27 | 2021-07-29 | 5,150,751 | — | $0 | 0 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | C Conversion | 2021-07-27 | 2021-07-29 | 507,724 | — | $0 | 507,724 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2021-07-27 | 2021-07-29 | 187,214 | $17.00 | $3.18M | 1,185,767 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | C Conversion | 2021-07-27 | 2021-07-29 | 998,553 | — | $0 | 998,553 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | P Buy | 2021-07-27 | 2021-07-29 | 2,762,786 | $17.00 | $46.97M | 7,913,537 | SEC↗ |
| CTKB Cytek Biosciences, Inc. | C Conversion | 2021-07-27 | 2021-07-29 | 5,150,751 | — | $0 | 5,150,751 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | C Conversion deriv | 2021-07-06 | 2021-07-08 | 588,850 | — | $0 | 0 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | C Conversion deriv | 2021-07-06 | 2021-07-08 | 1,184,366 | — | $0 | 0 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | C Conversion deriv | 2021-07-06 | 2021-07-08 | 6,122,557 | — | $0 | 0 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | C Conversion | 2021-07-06 | 2021-07-08 | 588,850 | — | $0 | 588,850 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | C Conversion | 2021-07-06 | 2021-07-08 | 6,122,557 | — | $0 | 6,122,557 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | P Buy | 2021-07-06 | 2021-07-08 | 1,759,332 | $16.00 | $28.15M | 7,881,889 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | C Conversion | 2021-07-06 | 2021-07-08 | 1,184,366 | — | $0 | 1,184,336 | SEC↗ |
| ABOS Acumen Pharmaceuticals, In | P Buy | 2021-07-06 | 2021-07-08 | 115,668 | $16.00 | $1.85M | 1,300,034 | SEC↗ |